All entries for: Immune Diseases

May 22, 2026

Novartis

Layoffs

Basel, Baselstadt

10,000+ employees

Novartis is continuing to trim its workforce in the U.S., letting go of 76 employees in East Hanover, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) Act alert for the state. The layoffs will take effect on Aug. 21.

This will be the third time this year that Novartis downsized its New Jersey operations. The first batch of layoffs was announced in March, affecting 114 employees set to take effect from June 26 through Nov. 27. The second hit came a month later, with 60 jobs projected to be cut from July 24 through Nov. 20.

Novartis earlier this month also announced that it would close down a production site in Germany by the end of 2028, eliminating 220 jobs in the process.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple

Drug Type: Biologic, Small Molecule

Source

May 15, 2026

Novartis

Layoffs

Basel, Baselstadt

10,000+ employees

Novartis is letting go of “a select number” of employees within its biomedical research organization, a company spokesperson confirmed to BioSpace in an emailed statement.

“Novartis continually assesses opportunities to support our growth strategy as a focused innovative medicines company,” the statement read. “We regularly evaluate our organizational setup to ensure it remains aligned with evolving priorities.”

The cuts are the latest in a series of made or projected layoffs at Novartis this year that in total affect nearly 400 employees. Earlier this month, the Swiss pharma announced plans to shutter a production facility in Wehr, Germany, by the end of 2028. Novartis expects that closure will eliminate 220 jobs. In March and April, the pharma disclosed between two Worker Adjustment and Retraining Notification (WARN) Act notices that it will let go of 174 employees in East Hanover, New Jersey. Of those cuts, layoffs affecting 114 people are effective June 26 through Nov. 27, while those impacting 60 staffers run from July 24 through Nov. 20.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple, Oncology

Drug Type: Biologic, Small Molecule

Source

May 15, 2026

Takeda

Layoffs

Tokyo

10,000+ employees

To cut back on costs, Takeda is rolling out a sweeping “transformation program” that will streamline corporate operations and see some 4,500 employees let go in fiscal year 2026, according to an earnings presentation. That number represents less than 10% of total roles globally and does not reflect hiring plans, a company spokesperson told BioSpace in an emailed response on May 13.

“Right now, we have 2,200 open roles globally and we expect to create new jobs throughout the year, which we are prioritizing filling with internal candidates,” the spokesperson said.

The layoffs will look different across the organization and will be phased according to unique business needs and country requirements, according to the spokesperson. They confirmed that the cuts include an estimated 247 roles in Massachusetts and 387 in other states outlined in a March Worker Adjustment and Retraining Notification (WARN) Act notice.

Disease Area: Dermatology, Immune Diseases, Multiple, Neurological Diseases, Oncology, Rare Diseases

Drug Type: Biologic, Small Molecule

Source

May 14, 2026

First Tracks Biotherapeutics, Inc.

Neutral Outlook

San Diego, CA

51-200 employees

Thus, it is unclear how the IRA will be implemented but it will likely have a significant impact on the pharmaceutical industry and the pricing of our products and product candidates.

Disease Area: Chronic Disease, Immune Diseases

Drug Type: Biologic

Source

May 14, 2026

Candel Therapeutics, Inc.

Neutral Outlook

Needham, Massachusetts

51-200 employees

While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain that it will not affect our patent strategy in the long run.

Disease Area: Immune Diseases, Oncology

Drug Type: Biologic

Source

May 13, 2026

Adicet Bio, Inc.

Neutral Outlook

Redwood City, CA

51-200 employees

The effects of the IRA on our business and the healthcare industry in general is not yet known.

Disease Area: Hematology, Immune Diseases, Oncology

Drug Type: Biologic

Source

May 12, 2026

CalciMedica, Inc.

Neutral Outlook

La Jolla, California

1-50 employees

While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.

Disease Area: Cardiology, Gastrointestinal, Immune Diseases, Respiratory Diseases

Drug Type: Small Molecule

Source

May 12, 2026

Nkarta, Inc.

Neutral Outlook

South San Francisco, California

51-200 employees

The effect of the IRA on our business and the healthcare industry in general is not yet known, but we continue to evaluate its potential impact.

Disease Area: Chronic Disease, Immune Diseases, Rare Diseases

Drug Type: Biologic

Source

May 11, 2026

Sana Biotechnology, Inc.

Negative Outlook

Seattle, Washington

51-200 employees

If we obtain regulatory approval for any of our product candidates, the IRA could substantially and negatively impact the prices we may charge for such products, which could harm our ability to generate revenue and achieve and sustain profitability.

Disease Area: Endocrinology, Hematology, Immune Diseases, Oncology

Drug Type: Biologic

Source

May 11, 2026

Septerna, Inc.

Neutral Outlook

South San Francisco, CA

51-200 employees

The effects of the IRA on our business and the healthcare industry in general is not yet known.

Disease Area: Dermatology, Endocrinology, Immune Diseases, Metabolic Diseases

Drug Type: Small Molecule

Source